ReviewMolecular biomedicine2026
The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The Jumonji C domain-containing (JMJD) family of histone demethylases constitutes an essential class of epigenetic regulators that dynamically sculpt gene expression programs through the erasure of methyl groups from histone lysine and arginine residues. Dysregulation of these enzymes is increasingly implicated in the pathogenesis of a wide spectrum of human diseases. Yet, a fragmented, disease-specific understanding has thus far hindered a unified view of their functions across different pathological states. In this review, we provide a comprehensive and comparative analysis of the JMJD family, synthesizing their roles and mechanisms across diverse human conditions, including cancer, neurological disorders, inflammatory, autoimmune, cardiovascular, and metabolic diseases. We highlight that individual JMJD proteins can function paradoxically as both promoters and suppressors of pathology, a duality determined by the specific cellular and pathological context. A key novelty of our work is its integrated, cross-disease perspective, which moves beyond conventional silos to illuminate common pathophysiological pathways and unique regulatory networks orchestrated by these epigenetic erasers. Furthermore, we critically assess the associated therapeutic landscape, summarizing advances in the development of small-molecule JMJD inhibitors and discussing innovative strategies to tackle enduring challenges, such as enzymatic redundancy and selectivity. By integrating insights from disparate disease models, this review seeks to forge a holistic understanding of JMJD biology and accelerate the development of novel epigenetic therapeutics directed at this pivotal protein family.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.